For US payers, pegfilgrastim is a less-expensive choice than daily filgrastim for reducing the risk of febrile neutropenia in patients receiving myelosuppressive chemotherapy.
Gregory Hill, BA
Advertisement
Articles by Gregory Hill, BA
Advertisement
Latest Updated Articles
- Economic Model of Granulocyte Colony-Stimulating Factors for Patients Receiving Chemotherapy
Published: December 11th 2012 | Updated:
Advertisement
Advertisement
Trending on Pharmacy Times
1
Amivantamab for EGFR-Mutated Metastatic Non–Small Cell Lung Cancer
2
Celebrating the Pharmacist’s Impact: How Pharmacists Elevate Care in Every Setting
3
FDA Approves 1-Minute HIV Self-Test
4
How Pharmacists Can Navigate Legal Complexities With Most Favored Nation Status
5
